DOCETAXEL

Docetaxel stabilizes microtubules and prevents mitotic spindle disassembly, used in breast, lung, and prostate cancers. Side effects include neutropenia, neuropathy, fluid retention, mucositis, and alopecia.

Category:

Product Description


Mechanism of Action

DOCETAXEL (ID 30152) displays a high‑dimensional biochemical interaction profile, integrating catalytic‑domain modulation, multi‑axis signalling interference, mitochondrial‑network recalibration, ion‑flux redistribution, membrane‑potential rebalancing, cytoskeletal remodelling, redox‑equilibrium restructuring and transcription‑factor pathway reprogramming. Its molecular topology supports interaction with catalytic residues, allosteric microdomains, transmembrane helices, nucleotide‑binding pockets, redox‑buffer centres and polymeric scaffolding complexes, enabling wide‑band influence across metabolic, genomic, structural and electrophysiological layers.

At the signalling level, DOCETAXEL may reconfigure phosphorylation landscapes spanning ERK/MAPK/JNK/p38 and PI3K–AKT axes, modulate G‑protein coupling states, reorganise Ca²⁺ microdomain geometry, adjust IP₃/DAG cascade topology, and recalibrate cAMP–PKA amplitude distributions. Mitochondrial effects can include ETC‑complex rebalancing, ATP/ADP flux modulation, ROS‑threshold displacement, membrane‑potential polarity shifts and bidirectional stress‑signal integration between ER and mitochondrial compartments.

Advanced Research Applications

  • Kinome‑scale catalytic‑cascade interference mapping
  • High‑resolution docking & conformational‑transition simulations
  • UPR/ER‑stress, mitophagy & autophagic‑flux network analysis
  • Full multi‑omics integration (RNA‑seq, proteomics, phosphoproteomics, metabolomics)
  • Cytoskeletal mechanics & polymer‑turnover/force‑distribution modelling
  • Cell‑fate pathway simulations (apoptosis, necroptosis, ferroptosis, parthanatos)
  • AI‑driven SAR/QSAR pipelines for compound‑performance prediction

Toxicodynamics & Hazard Spectrum

  • Rapid ROS escalation & antioxidant‑buffer saturation
  • Mitochondrial fragmentation or ETC‑axis suppression
  • Severe Na⁺/K⁺/Ca²⁺ ionic‑flux destabilisation
  • Cytoskeletal depolymerisation & membrane‑integrity loss
  • Hyperactivation of NF‑κB, STAT & IRF inflammatory regulators
  • Induction of multi‑axis programmed‑cell‑death pathways
  • Epigenetic drift including methylation/acetylation imbalance

For expert laboratory research only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C43H53NO14

Molecular Weight

807.9 g/mol

CAS Number

114977-28-5

Storage Condition

Store between 2 °C and 25 °C (36 °F and 77 °F). Retain in the original package to protect from light. Freezing does not adversely affect the product.

Solubility

Insoluble

Purity

Purity information is available upon request (COA).

Synonym

docetaxel; 114977-28-5; Taxotere; Docetaxel anhydrous; Docetaxel Kabi

IUPAC/Chemical Name

[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate

InChl Key

ZDZOTLJHXYCWBA-VCVYQWHSSA-N

InChl Code

InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/148124;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download